MYRFL

Across TCGA pan-cancer cohorts, MYRFL RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated MYRFL data layer compared with 2 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher MYRFL RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYRFL expression acts as an unfavorable survival marker, although some lineages such as KIRP and STAD show a favorable association.

MESO, KIRP, and STAD are the cancer types where MYRFL RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Tertile	II,III,IV	0.277	0.569	<.001	88	view →
KIRP	DFS	Tertile	All	0.928	0.425	<.001	59	view →
STAD	OS	Median	All	0.744	0.582	.001	39	view →
ESCA	OS	Median	All	0.449	1.000	.011	24	view →
LGG	DFS	Tertile	All	0.738	0.898	<.001	18	view →
THCA	DFS	Quartile	II,III,IV	0.500	0.973	<.001	13	view →
UVM	DFS	Tertile	II,III,IV	0.418	0.633	.033	12	view →
READ	DFS	Tertile	IV	0.255	0.691	.014	11	view →
CESC	DFS	Tertile	All	0.667	0.815	.010	10	view →
LUAD	OS	Median	II,III,IV	0.373	0.573	.028	9	view →
CHOL	DFS	Tertile	All	0.686	0.174	.022	6	view →
LIHC	OS	Quartile	All	0.854	0.637	.030	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

MYRFL–MESO (DFS)

Open the MESO breakdown →